The FGF2 Protein Diaries
123). It truly is noteworthy that GLS2 is tumorigenic in breast cancer124, and its expression could compensate for lack of Gls in MYC-induced mouse liver tumours40. This implies that GLS2 could confer resistance to GLS1-particular inhibitors, like the allosteric inhibitor BPTES or CB-839, and this resistance can be hypothetically avoided by using a